← Leaderboards
Alexander A Khromykh
Sir Albert Sakzewski Virus Research Ctr
$1,989,687
Attributed
$1,989,687
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $268.8K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,989,687 · 3
By mechanism
U01$1,257,687 · 1
R21$732,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Replicon”
- Jonathan Smith · Alphavax Human Vaccines, Inc.$20,943,892
- Charles M. Rice · Rockefeller University$17,960,348
- Richard J. Kuhn · Purdue University$15,751,691
- Jeffrey D Chulay · Alphavax Human Vaccines, Inc.$13,968,680
- Barton F Haynes · Duke University$10,283,290
- Robert E. Johnston · University Of North Carolina Chapel Hill$9,919,523
Research focus
RepliconLaboratory MouseVaccine DevelopmentCytotoxic T LymphocyteFlaviviridaeEnzyme Linked Immunosorbent AssayPlasmidsFlavivirusAmino Acid SubstitutionFrequencies (Time Pattern)BenignBirdsCategoriesAntiviral ResponseAmericanAnimalsEncephalitisAttenuatedDengueDesignAttenuationDoseAnimal ModelCrows
Grant awards (9)
Attenuated West Nile virus vaccine$237,405
U01 · FY2009 · AI · contact PI
Attenuated West Nile virus vaccine$241,527
U01 · FY2008 · AI · contact PI
Attenuated West Nile virus vaccine$249,732
U01 · FY2007 · AI · contact PI
Attenuated West Nile virus vaccine$260,179
U01 · FY2006 · AI · contact PI
Attenuated West Nile virus vaccine$268,844
U01 · FY2005 · AI
Development of Kunjin replicon-based Ebloa vaccine$216,000
R21 · FY2004 · AI
Development of Kunjin replicon-based Ebloa vaccine$216,000
R21 · FY2003 · AI
KUNJIN VIRUS REPLICON AS A VECTOR FOR HIV VACCINE.$150,000
R21 · FY2001 · AI
KUNJIN VIRUS REPLICON AS A VECTOR FOR HIV VACCINE.$150,000
R21 · FY2000 · AI